NCT07200102View on ClinicalTrials.gov

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

January 31, 2029

Study Completion Date

December 31, 2030

Conditions
Multiple Myeloma
Interventions
DRUG

Selinexor

Selinexor will be provided by Karyopharm Therapeutics, Inc.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

Washington University School of Medicine

OTHER